Isomorphic Labs raises $5 billion Series C for SI drug design
Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .
Isomorphic Labs now has $5 billion in new capital aimed at IsoDDE, more than 20 partner programmes and moving candidates into clinical trials.
Isomorphic Labs, Alphabet's SI drug-design unit, raised $5 billion in a Series C round, Bloomberg reported. Greenoaks and Sequoia Capital co-led the round, Andreessen Horowitz (a16z) joined as a new investor, and Alphabet made a significant investment. All existing shareholders took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Bloomberg had previously reported a valuation of about $50 billion. This is the second major round in six months, after a $2.1 billion Series B in May. The money will go to the IsoDDE engine, more than 20 programmes with Eli Lilly, Novartis and Johnson & Johnson, and moving candidates into clinical trials.